SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm

Abstract

Antibody-drug conjugates (ADC) target cytotoxic drugs to antigen-positive cells for treating cancer. After internalization, ADCs with noncleavable linkers are catabolized to amino acidlinker-warheads within the lysosome, which then enter the cytoplasm by an unknown mechanism. We hypothesized that a lysosomal transporter was responsible for delivering noncleavable ADC catabolites into the cytoplasm. To identify candidate transporters, we performed a phenotypic shRNA screen with an anti-CD70 maytansine-based ADC. This screen revealed the lysosomal membrane protein SLC46A3, the genetic attenuation of which inhibited the potency of multiple noncleavable antibodymaytansine ADCs, including ado-trastuzumab emtansine. In contrast, the potencies of noncleavable ADCs carrying the structurally distinct monomethyl auristatin F were unaffected by SLC46A3 attenuation. Structure-activity experiments suggested that maytansine is a substrate for SLC46A3. Notably, SLC46A3 silencing led to relative increases in catabolite concentrations in the lysosome. Taken together, our results establish SLC46A3 as a direct transporter of maytansine-based catabolites from the lysosome to the cytoplasm, prompting further investigation of SLC46A3 as a predictive response marker in breast cancer specimens. Cancer Res; 75(24); 5329-40. Ó2015 AACR.

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

“…Lysosomal delivery of T-DM1 is another key event and the results of this study show that alternative T-DM1 internalization and trafficking parameters can influence lysosomal accumulation of T-DM1. The mechanism of lysosomal escape of lysine-MCC-DM1 (the released species of T-DM1) has long been debated but the recent description of SLC46A3 as a lysosomal membrane transporter protein that mediates the lysosome-to-cytoplasm transfer of this metabolite has provided insights into potential mechanisms of transport (28).…”

Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy

“…For T-DM1, the more hydrophilic nature of the metabolite results in few bystander effects (relative to more lipophilic conjugates that can diffuse out of the original targeted cell(80) or from the interstitium(81) and into a local cell(3)). Cytosolic access of hydrophilic metabolites may even require transporters within the target cell for toxicity(82). Bystander effects from more lipophilic payloads such as MMAE may explain why higher DAR can improve efficacy with the same antibody dose (e.g.…”

A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells

“…The rate of efflux of the uncharged CX ADC catabolites out of the lysosomes is expected to be greater than that for the charged lysine-SMCC-DM1 catabolite, which could be transported slowly out of lysosomes in some cells. In a recent report, knockdown of a lysosomal membrane protein (SLC46A3) resulted in the abrogation of cytotoxicity of SMCC-DM1 conjugates in several cell lines (35). Cell lines with deficient lysosomal transport of lysine-SMCC-DM1 catabolite (due to low levels of lysosomal export proteins such as SLC46A3) could possibly be sensitive to killing by CX ADC as the uncharged DM-CX1 and DM-CX2 catabolites may diffuse out of acidic lysosomes without requiring specific lysosomal transporters.…”